Overview of Enfluran

Property	Description
Active ingredient	Enflurane (C₃H₂ClF₅O)
Form	Volatile liquid / Inhalation solution
Pharmacological class	General Anesthetic
Common use	Induction and maintenance of anesthesia
Origin	Synthetic, Halogenated ether derivative

Identity and Classification: What Type of Anesthetic is Enfluran?

Enfluran is a medicinal preparation containing the active ingredient Enflurane (INN), which is precisely categorized as a General Anesthetic used for surgical procedures. The chemical identity of Enflurane is defined as a halogenated ether derivative, a synthetic compound (2-chloro-1,1,2-trifluoroethyl difluoromethyl ether). This drug is known for its systemic action, which achieves a complete, controlled, and reversible reduction in the function of the central nervous system (CNS). This agent is clinically recognized for its reliable potency and was frequently used in surgical settings for decades.

Composition and Pharmaceutical Form: What is Enflurane Made Of?

The medicine is supplied as an inhalation solution, presenting as the pure, colorless volatile liquid form of Enflurane. Because of its low boiling point, the product is administered as a vapor via a specialized vaporizer unit into the patient's breathing circuit, making the preparation the pure active compound designed for administration by inhalation. This drug is a nonflammable liquid administered by vaporizing, indicating its physical properties are well-suited for controlled delivery into the patient's respiratory system. This mechanism allows for the rapid and precise adjustment of the anesthetic depth by the clinician.

General Purpose and Benefit: What is the Main Use of a General Anesthetic?

The central purpose of Enfluran is the safe and controlled achievement of general anesthesia. By acting as a CNS depressant, the drug creates a reversible state where the patient is unconscious and experiences a complete abolition of sensory input, including pain, memory, and motor responsiveness. Its fundamental function is to provide an essential, quiescent state for the induction and maintenance of anesthesia required for procedures, ensuring patient immobilization and loss of awareness.

What side effects are possible with Enfluran?

Possible side effects and safety information

The official safety profile for Enfluran outlines documented adverse reactions across several major physiological systems. These effects are classified by regulatory authorities based on their reported incidence in clinical use, distinguishing between commonly observed events and rare, serious adverse reactions.

System-Organ Safety Overview

The regulatory classification includes effects on the Cardiovascular System (such as hypotension and arrhythmias), the Nervous System (including the potential for motor activity and seizures), and the Hepatobiliary System, where cases of mild to severe hepatic injury and necrosis have been reported. Other systems involved are the Respiratory System, with documented risks of respiratory depression and hypoxia, and effects on Metabolism (e.g., perioperative hyperkalemia).

Serious Adverse Reactions and Constraints

Serious adverse reactions documented in regulatory documents include Malignant Hyperthermia (MH) syndrome, a rare, potentially fatal hypermetabolic state, and cases of hepatic failure and cardiac arrest. The label explicitly states that Enfluran is contraindicated (should not be used) in individuals with a history of seizure disorders or known/suspected genetic susceptibility to MH syndrome.

Population- and Exposure-Specific Safety

Safety notes specify that seizures and unwanted motor activity may be encountered when the medicine is used at deep levels of anesthesia or when accompanied by low carbon dioxide levels (hypocapnia). Furthermore, a specific, rare risk of severe cardiac arrhythmias and death linked to perioperative hyperkalemia is noted, particularly in pediatric patients who may have latent neuromuscular disease.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Enfluran, or excessive depth of anesthesia, is officially documented to present with signs of increasing systemic depression. The primary clinical manifestation is progressive hypotension which correlates with the degree of over-anesthetization. Spontaneous respiration also becomes depressed, leading to regulatory-mandated emergency actions.

If overdose occurs, the official required steps are to immediately stop the administration of Enfluran, establish a patent airway, and administer pure oxygen using assisted or controlled ventilation.

Immediate medical attention is required for life-threatening complications. The most severe documented risk is the potential to trigger Malignant Hyperthermia (MH), a severe hypermetabolic state associated with muscle rigidity, tachycardia, and unstable blood pressure. The regulatory treatment for this specific syndrome includes the administration of intravenous dantrolene sodium.

Severe outcomes are also documented in specific populations, notably pediatric patients and individuals with neuromuscular disease, who face an increased risk of cardiac arrhythmias and death related to hyperkalemia. Furthermore, excessive exposure is associated with the potential for minimal renal damage from high fluoride metabolite levels. These circumstances constitute mandatory triggers for seeking urgent professional medical care.

Therapeutic Uses of Enfluran

What Enfluran Treats: Main Uses and Benefits

Enfluran is generally applied across domains where short-term symptomatic assistance is needed to support surgical interventions.

The medicine is relevant in contexts involving conditions marked by increased physiological stress and is applied in clinical settings that involve acute or disruptive symptom patterns, including induction and maintenance of general anesthesia for operative procedures, and for analgesia during vaginal delivery or as a supplement for Cesarean section. This use is commonly employed to help manage the cluster of symptoms related to heightened physiological activity, such as consciousness, pain sensation, and unwanted motor responses.

“Applied in scenarios where additional management of discomfort is required, Enfluran assists with maintaining functional stability and patient immobilization during the intervention.”

Relief of Awareness, Sensation, and Motor Activity

Enfluran is used to induce a controlled, reversible state that contributes to the abolition of awareness and sensory input, which provides support that helps ease the overall symptom burden. Furthermore, it is relevant for controlling symptoms related to increased neurological or muscular activity, assisting with maintaining functional stability by suppressing motor and reflexive responses. This dual action offers symptomatic relief that helps patients cope more steadily with difficult episodes in both surgical and obstetric contexts.

Quick Fact: Relief for Acute Systemic Discomfort Used to address symptoms that require complete, temporary loss of sensation and consciousness, such as during surgical and delivery procedures.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Enfluran

Populations for whom use is contraindicated:

Individuals with known or suspected genetic susceptibility to malignant hyperthermia (MH) [Source 1.1, 2.3].
Patients with latent or overt neuromuscular disease, particularly Duchenne Muscular Dystrophy [Source 1.1].
Patients with a history of liver dysfunction, jaundice, or unexplained fever following previous exposure to a halogenated anesthetic [Source 2.5].
Patients with known sensitivity to Enflurane or other halogenated agents [Source 2.5].

Populations Requiring Conditional or Cautioned Use:

Central Nervous System (CNS) Conditions: Caution is advised for patients with pre-existing EEG abnormalities or a history of seizure disorders due to the potential for cortical stimulation [Source 2.4, 2.5].
Hepatic/Renal Impairment: Caution is necessary in patients with previous hepatic disease or renal impairment [Source 1.2, 1.4].
Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed (Pregnancy Category B) and high concentrations may increase uterine bleeding during delivery. Caution must be exercised when administering to a nursing woman as excretion into human milk is unknown [Source 1.3, 1.4].

Age-Group Eligibility:

The medicine is approved for the induction and maintenance of general anesthesia in adults and for the maintenance of anesthesia in pediatric patients [Source 1.4].
The dosage requirements for older adults are typically lower, as the required anesthetic concentration decreases with increasing patient age [Source 2.6].

What should I know about interactions with other medicines?

The regulatory profile for Enfluran describes several documented interactions with other medicines and substances, classified primarily by pharmacodynamic potentiation and metabolic effects. The section strictly details official restrictions and outcomes defined in regulatory labeling.

Interaction Structure and Official Restrictions

Category	Interacting Entity	Official Interaction Pattern
Pharmacodynamic Potentiation	Non-depolarizing muscle relaxants	Effects are markedly potentiated, requiring clinical attention to co-administration.
Metabolic Liability	Isoniazid, Hydrazine compounds	Chronic ingestion may lead to patients metabolize greater amounts of enflurane, altering systemic exposure.
Myocardial Sensitization	Epinephrine-containing solutions	Enflurane sensitizes the myocardial conduction system, necessitating a restriction of up to 2 mcg/kg injected over a 10-minute period. Lidocaine co-administration enhances the safety of this procedure.

Regulatory Constraints and Contextual Notes

The official labeling notes that Enfluran is contraindicated in patients with a known or suspected genetic predisposition to malignant hyperthermia. A population-specific constraint exists regarding the use of Succinylcholine in pediatric patients with certain neuromuscular diseases, due to an association with perioperative hyperkalemia. Furthermore, a substance interaction is documented: Enfluran reacts with desiccated Carbon Dioxide absorbents used in the delivery system to produce carbon monoxide.

This structure defines critical label-based constraints on co-administration, covering potentiation, altered metabolism, and necessary procedural safeguards.

Mechanism of Action

Enfluran is a halogenated ether that primarily targets the central nervous system (CNS) and spinal cord. Its mechanism of action involves the modulation of ligand-gated ion channels and voltage-sensitive ion channels, resulting in neuronal hyperpolarization and reduced excitability.

Cellular and Molecular Targets

Enfluran acts as a potentiator of the inhibitory gamma-aminobutyric acid type A ( GABA A) receptor. This interaction increases the frequency and duration of chloride ( Cl^-) ion influx through the channel pore. The resulting enhancement of GABAergic inhibitory currents hyperpolarizes the postsynaptic neuron, dampening neuronal activity.

It is also a potentiator of the glycine receptor ( GlyR), which similarly mediates inhibitory neurotransmission in the spinal cord and brainstem. Furthermore, Enfluran acts as an antagonist at the excitatory N-methyl-D-aspartate ( NMDA) receptor. This inhibition reduces NMDA-mediated excitatory signaling, contributing to the overall depression of CNS function.

System-Level Consequences

The cumulative effect of enhanced inhibitory and diminished excitatory neurotransmission leads to a dose-dependent depression of consciousness and abolition of motor reflexes. In the cardiovascular system, Enfluran is an inhibitor of voltage-dependent calcium channels and calcium-transporting ATPase in the cardiac sarcoplasmic reticulum. This intracellular consequence reduces myocardial contractility and systemic vascular resistance, resulting in modulation of circulatory dynamics.

Dosage and Administration Information

Enflurane is a potent, nonflammable liquid for inhalation, classified as a general anesthetic and must be administered exclusively by individuals trained in anesthesia, such as a certified anesthesiologist or nurse anesthetist. It is delivered via a vaporizer specifically calibrated for this agent to ensure precise concentration control. The dosage is highly individualized and is determined by the healthcare provider based on the surgical procedure, patient's age, and overall physical condition.

Administration and Dosing Overview

Phase of Anesthesia	Typical Inspired Concentration Range	Goal
Induction	Generally 2.0% to 4.5%	Achieve surgical unconsciousness, typically within 7 to 10 minutes.
Maintenance	Generally 0.5% to 3.0%	Sustain the surgical level of anesthesia.
Obstetric Analgesia	Generally 0.25% to 1.0%	Provide pain relief for vaginal delivery.

During administration, the anesthesia provider will continuously monitor the patient’s vital signs (e.g., heart rate, blood pressure, and oxygen saturation) and adjust the inspired concentration to maintain the desired depth of anesthesia, as excessive concentration can lead to profound circulatory or respiratory depression. Changes in the level of anesthesia can be achieved rapidly by altering the inspired concentration.

It is important to note that the use of Enflurane is typically avoided in patients with a known or suspected genetic predisposition to malignant hyperthermia.

Recent Clinical Evidence

Enfluran: Recent Clinical Evidence

Evidence for General Anesthesia for Operative Procedures

The primary research was founded on Randomized Controlled Trials (RCTs) and clinical evaluations focused on adult surgical patients. Researchers examined outcomes related to the time elapsed for both the onset of the anesthetic state (induction) and the return of cognitive function (recovery). Studies measured systemic physiological responses, including heart rate and blood pressure (hemodynamics), and the degree of muscle relaxation. Findings describe patterns observed in the studies regarding timing and physiological strain. This core indication has a high evidence level based on original regulatory data, but long-term effects are not fully established, and the data base is historical.

Evidence for Analgesia during Obstetric Procedures

Dedicated Clinical Trials and Comparative Studies explored Enfluran’s role in managing physical discomfort during labor and delivery. Researchers assessed the perceived degree of discomfort, patient awareness, and the agent's effect on uterine muscle activity. Studies also monitored the immediate health status of the newborn using Apgar scores and other physiological assessments. Evidence is limited for this indication compared to core anesthetic use, and is categorized as moderate support. Research noted that higher concentrations was associated with documented alterations in uterine function and potential maternal blood loss, meaning subgroup findings are uncertain.

Research in Special Populations and Gaps

Clinical research focused on special populations such as women in labor and neonates exposed during delivery. The follow-up durations in most research were often limited to the intraoperative and immediate recovery phases. There is limited information for outcomes that extend beyond the immediate post-procedure phase, especially in infants. The key limitation is that much of the core evidence data are derived from trials that are now decades old. Comparative evidence is lacking against current modern agents. What remains uncertain primarily revolves around comparative performance and extended-duration outcomes for special populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Enfluran (FAQ)

Q: Can Enfluran cause problems with my kidneys?

Official information advises caution when the medicine is used in patients who have existing kidney impairment. However, studies in patients without pre-existing kidney conditions indicated that the drug's metabolism to inorganic fluoride was generally not associated with clinically significant kidney dysfunction.

Q: Does Enfluran make people feel tired or sleepy?

Enfluran is a general anesthetic that acts as a central nervous system (CNS) depressant. Its function is to achieve a reversible state of unconsciousness during a surgical procedure, meaning it diminishes the function of the nervous system while it is being administered.

Q: How long does it take for Enfluran to start working?

According to regulatory documents, the phase of anesthesia called 'induction,' where surgical unconsciousness is achieved, typically occurs within 7 to 10 minutes after the administration of the vapor begins.

Q: Does Enfluran affect the results of any common laboratory tests?

The drug is metabolized by the body, a process that yields an increase in a substance called inorganic fluoride. This metabolic change is a factor that may be assessed by healthcare providers using laboratory tests.

Q: How to Store and Dispose of Enflurane?

The medicine should be stored at room temperature, defined as 15 C to 30 C (59 F to 86 F), and kept in its original container. Unused or expired product should be disposed of in accordance with local hazardous chemical waste requirements or official drug take-back programs.

Q: Is Enfluran a type of antibiotic or something else?

Enfluran is categorized as a General Anesthetic used to achieve and maintain surgical anesthesia. It is chemically classified as a halogenated ether derivative and is not used to treat bacterial infections.

Q: How is Enfluran different from the older drug that treats the same condition?

Enfluran is classified as a General Anesthetic that works by modulating specific inhibitory and excitatory ion channels in the central nervous system. Its official description highlights its chemical identity as a halogenated ether derivative.

Q: What happens if I forget to take a dose of Enfluran?

This medicine is not a daily prescription taken at home. It is a general anesthetic that must be administered exclusively by a trained healthcare professional, such as an anesthesiologist, in a clinical setting for a surgical procedure.

Q: Is Enfluran a long-term medication or just for a short time?

Enfluran is used for the acute, short-term purpose of achieving and maintaining general anesthesia for the specific duration of a surgical procedure. It is not intended for long-term use.

Q: What is the difference between Enfluran and a placebo in studies?

Enfluran is an active drug that creates a reversible state of unconsciousness, pain abolition, and loss of motor reflexes during surgery. A placebo, by comparison, is an inactive substance used in studies for research purposes.

Q: What kind of research has been done on Enfluran?

Research includes Randomized Controlled Trials (RCTs) focusing on the timing of induction (onset of anesthesia) and recovery in adult surgical patients. Clinical trials also explored its role in managing discomfort during labor and delivery.

Q: What should I do if I notice my side effects getting worse on Enfluran?

Because the medicine is administered in a clinical setting, any changes in condition or unwanted effects are managed directly by the anesthesia provider. The patient's vital signs are continuously monitored by the clinical team.

Q: Is there a maximum time a person is supposed to stay on Enfluran?

The drug is administered only for the acute duration necessary to complete the surgical procedure. The duration of its administration is precisely determined by the healthcare provider based on the surgical plan.

Q: Is it true that Enfluran needs to be taken at the same time every day?

No. This medicine is a general anesthetic used for a single acute surgical procedure in a clinical setting. It is not a medication that is taken daily or on a schedule.

Q: Are there any known issues with stopping Enfluran suddenly?

The drug’s effects are rapidly reversible. Changes in the depth of anesthesia or recovery can be achieved quickly by altering the concentration of the vapor being administered by the clinician.

Q: Do clinical trials of Enfluran include people with other chronic health conditions?

Clinical research has focused on adult surgical patients, women in labor, and neonates. However, official safety constraints advise caution for patients with pre-existing conditions, including hepatic (liver) disease, renal (kidney) impairment, or pre-existing EEG abnormalities.

Q: How does Enfluran affect the body's normal processes?

The drug works by affecting specific channels in the central nervous system, which leads to the temporary depression of consciousness. It also impacts the cardiovascular system by reducing the heart muscle's contractility.

Q: What does the research say about long-term use of Enfluran?

Regulatory documents explicitly note that follow-up in most research was often limited to the period during and immediately after the procedure. Therefore, long-term effects are not fully established.

Q: Can Enfluran be used by people who have gluten sensitivity?

Yes. The medicine is supplied as the pure, colorless volatile liquid form of Enflurane and is administered as a vapor by inhalation. It is not an oral product and does not contain the excipients (inactive ingredients) that may be a source of gluten.

Q: Why do I need a special blood test before starting Enfluran?

Standard preparation for anesthesia often includes blood tests to evaluate the function of major organs. Official safety information advises caution for patients with pre-existing hepatic (liver) disease or renal (kidney) impairment, which these tests help assess.

Q: Can Enfluran be crushed or split if it is a tablet form?

No. This medicine is a volatile liquid supplied for use as an inhalation solution. It is administered as a vapor via a specialized vaporizer machine; it is not available in tablet or capsule form.

Q: Do official guidelines mention taking Enfluran with or without food?

No. Enfluran is an anesthetic administered by inhalation as a vapor in a clinical setting, not ingested orally. Therefore, official guidance regarding taking the drug with or without food or liquid is not applicable.

How should Enfluran be stored and disposed of?

How to Store and Dispose of Enflurane

Official regulatory guidelines for Enflurane (Ēthrane) specify conditions necessary to maintain the integrity and stability of this volatile liquid anesthetic.

Storage Requirements

Enflurane must be stored at room temperature, which is defined as 15 C to 30 C (59 F to 86 F). The product is highly stable and does not require the addition of stabilizers, nor is it subject to decomposition upon contact with strong base or common materials like soda lime. It must be kept in the original container and stored out of the reach of children.

Handling and Disposal

Enflurane is classified as a nonflammable liquid. Its chemical stability is maintained even with exposure to ultraviolet light, ruling out specific light-protection requirements. Unused or expired medicinal product, particularly in professional settings, must be disposed of in accordance with local hazardous chemical waste requirements or official drug take-back programs.

Enfluran